Cooley Helps Crescendo in $270 Million Sale to Myriad

, The Recorder

   | 0 Comments

PALO ALTO — South San Francisco's Crescendo Bioscience Inc., a maker of rheumatoid arthritis tests, and a Palo Alto team from Cooley hit a high note on the company's $270 million acquisition by Myriad Genetics Inc. Salt Lake City-based Myriad, a molecular diagnostic company that last year was at the center of a high-profile Supreme Court patent case, tapped Mintz, Levin, Cohn, Ferris, Glovsky and Popeo of Boston for legal counsel.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202641986243

Thank you!

This article's comments will be reviewed.